Yao Yu

机构：Tongji University, Harbin Medical University, Wuhan University of Technology, Shanghai Chest Hospital, Wuhan University, Guilin University of Technology, Third Affiliated Hospital of Harbin Medical University, Zhujiang Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Shanghai Tenth People's Hospital, The University of Adelaide, Henan Normal University · ORCID：0000-0002-2513-8685

发表论文 53 篇 · 总被引 745 次 · h-index 16

代表论文

• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial (2025 · Nature Medicine · 被引 34)
• Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS) (2024 · 癌症：英文版 · 被引 28)
• Nanozymes as next-generation ROS scavengers: design strategies, catalytic mechanisms, and therapeutic frontiers (2025 · Journal of Materials Chemistry B · 被引 21)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• Advances in fluorescent probes of non-alcoholic fatty liver disease (2025 · Talanta · 被引 15)
• Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC). (2024 · Journal of Clinical Oncology · 被引 9)